Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.55 |
| ▸ | CA1 | P00915 | 2/20 | 0.55 |
| ▸ | CA2 | P00918 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | CA3 | P07451 | 1/20 | 0.55 |
| ▸ | CA4 | P22748 | 1/20 | 0.55 |
| ▸ | CA6 | P23280 | 1/20 | 0.55 |
| ▸ | CA5A | P35218 | 1/20 | 0.55 |
| ▸ | CA7 | P43166 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 1/20 | 0.55 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.55 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.55 |
| ▸ | FABP4 | P15090 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL279847 | 0.91 | NPC1 (0.51) | NPC1CA1CA2RAB9ACYP2C19 | |
| SCHEMBL12901004 | 0.82 | EGLN1 (0.55) | NPC1CA1CA2RAB9AHPGD | |
| SCHEMBL12900959 | 0.80 | CA1 (0.50) | NPC1CA1CA2RAB9ACA12 | |
| SCHEMBL2164508 | 0.79 | NAAA (0.57) | NPC1RAB9ACYP2C19CYP2C9SMN1; SMN2 | |
| SCHEMBL31661686 | 0.79 | NAAA (0.57) | NPC1RAB9ACYP2C19CYP2C9SMN1; SMN2 | |
| SCHEMBL12163930 | 0.79 | LMNA (0.53) | NPC1RAB9ACYP2C19HPGDP2RX7 | |
| SCHEMBL12900986 | 0.77 | FABP4 (0.56) | CA1CA2CA12CA3CA4 | |
| SCHEMBL14302731 | 0.77 | MAPK1 (0.49) | NPC1CA1CA2RAB9ACA12 | |
| SCHEMBL13962657 | 0.77 | POLB (0.67) | SMN1; SMN2 | |
| SCHEMBL31661859 | 0.76 | MAPK1 (0.55) | NPC1RAB9ACYP2C19CYP2C9SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7879887-B2 | such as 2-(4-chloro-3-hydroxyphenylamino)-N-(6H-pyrazolo[4',3':3,4]benzo[1,2-d]thiazol-2-yl)-acetamide, having antitumor activity, particularly dual inhibitory activity on Aurora kinase and cyclin-dependent kinase (CDK), and are useful for cell proliferative diseases such as cancer | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2011-02-01 | — | — | US | disclosed |
| US-20090275623-A1 | ALPHA-AMINO ACID DERIVATIVES AND MEDICAMENTS CONTAINING THE SAME AS AN ACTIVE INGREDIENT | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275623-A1 | ALPHA-AMINO ACID DERIVATIVES AND MEDICAMENTS CONTAINING THE SAME AS AN ACTIVE INGREDIENT | CCNA1, AURKA, CDK1 | NPC1 3238/4885CA1 2076/4885CA2 1115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.